Research / WTW / Fundamental state Inspectable configuration
State dimensions Filing 0000950170-24-018575 Insurance
Cash 33th Own-history percentile · N=9
Evidence method Level · gp.fundamentals.cash
$1.4B · CORE · VALID
Debt 100th Own-history percentile · N=9
Evidence method Level · gp.fundamentals.gross_debt
$7.4B · OPTIONAL · VALID
Net-income growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.fundamentals.net_income
4.56% · CORE · NOT_ENOUGH_HISTORY
Revenue growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.fundamentals.revenue
6.62% · CORE · NOT_ENOUGH_HISTORY
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 14 states Self-history eligible
Sep 30, 2022 0/4 normalized Level 3 Dec 31, 2022 0/4 normalized Level 3 Mar 31, 2023 0/4 normalized Level 3 Jun 30, 2023 0/4 normalized Level 3 Sep 30, 2023 2/4 normalized Level 3 Dec 31, 2023 2/4 normalized Level 3 Mar 31, 2024 2/4 normalized Level 3 Jun 30, 2024 2/4 normalized Level 3 Sep 30, 2024 4/4 normalized Level 3 Dec 31, 2024 4/4 normalized Level 3 Mar 31, 2025 4/4 normalized Level 3 Jun 30, 2025 4/4 normalized Level 3 Mar 31, 2026 4/4 normalized Level 3 Jun 30, 2026 4/4 normalized Level 4 Period transition
What moved in the state? Cash Increased
Previous $1.2B
Current $1.4B
Delta $177.0M Debt Increased
Previous $5.2B
Current $7.4B
Delta $2.2B Earnings Growth Increased
Previous -28.42%
Current 4.56%
Delta 32.98% Revenue Growth Decreased
Previous 10.17%
Current 6.62%
Delta -3.54% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.